DC
PEAR

Darrow Company’s Pear Therapeutics, Inc. Class A Common Stock PEAR Stock Holding History

Darrow Company’s Portfolio PEAR Stock Details PEAR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-154,711
Closed -$183K – 33
2022
Q4 		$183K Sell
154,711
-27,500
-15% -$57.8K 0.18% 32
2022
Q3 		$371K Buy
+182,211
New +$309K 0.39% 23

Other funds holding PEAR

Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
AV
Arboretum Ventures Ann Arbor, Michigan $1.72M AUM 82.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TAA
TB Alternative Assets Grand Cayman, Cayman Islands $623M AUM 154.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Darrow Company's PEAR Position: Q1 2023 in Review

Darrow Company sold out of Pear Therapeutics, Inc. Class A Common Stock (PEAR) in Q1 2023, closing a stake of 154,711 shares — an estimated $183K sold.

Darrow Company first reported a position in PEAR in Q3 2022 and held it in 2 quarters. The position peaked at $371K in Q3 2022. 53 funds tracked by Wall St. Rank hold PEAR as of Q1 2023.

  • Darrow Company reported no remaining Pear Therapeutics, Inc. Class A Common Stock position as of Q1 2023 after selling out during the quarter.
  • Darrow Company sold 154,711 Pear Therapeutics, Inc. Class A Common Stock shares in Q1 2023, an estimated $183K.
  • Darrow Company first reported a position in Pear Therapeutics, Inc. Class A Common Stock in Q3 2022 and held it in 2 quarters.
  • Darrow Company's Pear Therapeutics, Inc. Class A Common Stock position peaked at $371K in Q3 2022.
  • 53 funds tracked by Wall St. Rank held Pear Therapeutics, Inc. Class A Common Stock as of Q1 2023.

Based on Darrow Company's 13F filing for Q1 2023, filed 4 May 2023.